title: Ischemia-induced changes in brain levels of monoamines and their metabolites of mice and rats: some protective effects of naftidrofuryl.
abstract: Employing two types of brain ischemic animal models, an attempt was made to evaluate the protective effect of naftidrofuryl as the normalizing effect on the ischemia-induced changes in the brain levels of monoamines and metabolites. 1) During 2 min ligation of both left and right common carotid arteries of mice, dopamine (DA) content alone significantly decreased among three monoamines and four metabolites measured by a high performance liquid chromatography-electrochemical detection method. Pretreatment with naftidrofuryl oxalate (45 mg/kg, i.p.) was found to prevent the DA change, but the lower dose (15 mg/kg, i.p.) of the drug or any other drug tested individually (vinpocetine hydrochloride: 2 mg/kg, Ca hopantenate: 0.1 g/kg, citicoline: 0.1 g/kg, i.p.) had no such effect. 2) Infusion of carbon microsphere (500 particles/100 microliters of 20% dextran/1.5 min/rat) into the right internal carotid artery induced various degree of time-dependent changes in the behavior and also in the brain levels of monoamines and metabolites. Embolized rats which otherwise would survive for at least 6 d after infusion, were divided into the lightly-infarcted and severely-infarcted groups by grading the behavioral abnormality. Subsequent treatments with naftidrofuryl oxalate (15 mg/kg, i.p., twice daily, totally 4 times) which was begun 16 h after microsphere injection, was found to accelerate the recovery rate of brain dopamine level once decreased by the embolism though only in the lightly-infarcted group. The significance of the results obtained herein were discussed in relation to the clinical effectiveness of naftidrofuryl in human brain ischemic diseases.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nakamuta
authors.forename: K
authors.initials: K
authors.lastname: Muguruma
authors.forename: M
authors.initials: M
authors.lastname: Koida
authors.forename: Y
authors.initials: Y
authors.lastname: Hiramatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D007511:Ischemia / Q000378:metabolism*; D008297:Male; D051379:Mice; D009257:Nafronyl / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism
chemical_list: D015306:Biogenic Monoamines; D012701:Serotonin; D009257:Nafronyl; D004298:Dopamine; D009638:Norepinephrine